DOI:

10.37988/1811-153X_2025_2_82

Possibilities of ultrasound in the diagnosis of radioiodine-induced sialadenitis

Downloads

Authors

  • A.Ya. Razumova 1, PhD in Medical Sciences, associate professor of the Oral and maxillofacial surgery Department
    ORCID: 0000-0002-0415-3413
  • N.L. Petrov 1, PhD in Medical Sciences, associate professor of the Oral and maxillofacial surgery Department
    ORCID: 0000-0001-5182-1763
  • A.L. Vaaz 1, 5th year student at the Dental Faculty
    ORCID: 0009-0004-7893-4513
  • A.I. Yaremenko 1, Doctor of Science in Medicine, full professor of the Oral and maxillofacial surgery Department, vice-rector
    ORCID: 0000-0002-7700-7724
  • S.I. Kutukova 1, 2, Doctor of Science in Medicine, professor of the Oral and maxillofacial surgery Department, associate professor of the Oncology Department; oncologist at the Antitumor drug therapy ward
    ORCID: 0000-0003-2221-4088
  • E.V. Borodavina 3, PhD in Medical Sciences, senior researcher at the Division of radiosurgical treatment with closed radionuclides
    ORCID: 0000-0002-3306-5906
  • 1 Pavlov University, 197022, Saint-Petersburg, Russia
  • 2 Municipal clinical oncological dispensary, 198255, Saint-Petersburg, Russia
  • 3 A. Tsyb Medical radiological research centre, 249036, Obninsk, Russia

Abstract

Surgical approach is the leading method in the treatment of thyroid tumors. In some cases of treatment of differentiated thyroid cancer after surgical intervention it is necessary to use radioiodablation to remove the remaining thyroid cells or radioiodotherapy for patients in the group of intermediate and unfavorable forecast regarding the risk of progression. The salivary glands have the highest sensitivity to iodine after the thyroid gland, the accumulation of radiopharmaceutical leads to the formation of sialadenitis. Currently, there is no diagnostic protocol for this disease. The aim is to study the possibilities of ultrasound diagnostics of sialadenitis associated with radioiodotherapy.
Materials and methods.
A retrospective study analyzing two groups of patients was performed: Group I (n=30) with the diagnosis of sialadenitis induced by radioiodine therapy, Group II (n=30) of healthy volunteers without pathology in the maxillofacial region. Ultrasound diagnostics of salivary gland parameters and comparative analysis of the obtained results were performed.
Results.
There were 3 echographic signs of salivary glands condition in sialadenitis after radioiodotherapy distinguished: change of echogenicity, dilatation of the ductal system of salivary glands, inhomogeneity of the structure. Change of echogenicity occurs most often in the left PG — 6.7%. In patients with right and left PG lesions the ductal dilatation rate was 7.5% and 6.7%, respectively (dilatation up to 3 mm). Heterogeneity of salivary gland structure was most frequent in the left PG — 10%.
Conclusion.
The method of ultrasonic diagnostics is informative, time efficient in performance and data interpretation, has no absolute contraindications, therefore it can be a primary link in diagnostics of sialadenitis developed on the background of radioiodotherapy.

Key words:

sialadenitis, ultrasound, thyroid cancer, stenosis, radioiodotherapy

For Citation

[1]
Razumova A.Ya., Petrov N.L., Vaaz A.L., Yaremenko A.I., Kutukova S.I., Borodavina E.V. Possibilities of ultrasound in the diagnosis of radioiodine-induced sialadenitis. Clinical Dentistry (Russia).  2025; 28 (2): 82—87. DOI: 10.37988/1811-153X_2025_2_82

References

  1. Cronin K.A., Ries L.A., Edwards B.K. The surveillance, epidemiology, and end results (SEER) program of the National Cancer Institute. Cancer. 2014; 120 Suppl 23: 3755—7. PMID: 25412387
  2. Kitahara C.M., Sosa J.A. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016; 12 (11): 646—653. PMID: 27418023
  3. Ivanov V.K., Gorski A.I., Polkin V.V., Andreev V.G., Kashcheev V.V., Tumanov K.A., Ivanov S.A., Kaprin A.D. Dynamics of thyroid cancer incidence in the population of Russia: main risk factors. Radiation and Risk. 2022; 4: 6—20 (In Russian). eLIBRARY ID: 50081784
  4. Deng Y., Li H., Wang M., Li N., Tian T., Wu Y., Xu P., Yang S., Zhai Z., Zhou L., Hao Q., Song D., Jin T., Lyu J., Dai Z. Global burden of thyroid cancer from 1990 to 2017. JAMA Netw Open. 2020; 3 (6): e208759. PMID: 32589231
  5. Jin Y., Van Nostrand D., Cheng L., Liu M., Chen L. Radioiodine refractory differentiated thyroid cancer. Crit Rev Oncol Hematol. 2018; 125: 111—120. PMID: 29650270
  6. Evtushenko A.V., Gorchitsa Y.Y., Sizov P.A., Smirnov A.A. Modern tactics of treatment the cancer of thyroid gland. European Science. 2018; 4 (36): 80—89 (In Russian). eLIBRARY ID: 34913351
  7. Tsur N., Avishai G., Alkan U., Hod R., Shpitzer T., Bitton E., Gilat H. Ultrasonographic features of salivary glands after radioiodine therapy in patients with thyroid cancer. Laryngoscope. 2023; 133 (5): 1271—1275. PMID: 36354236
  8. Farkhutdinova L.M. Radioiodine therapy of papillary thyroid cancer, complicated by a radial myelitis. Clinical case. The Russian Archives of Internal Medicine. 2018; 3 (41): 223—230 (In Russian). eLIBRARY ID: 35002927
  9. Boucai L., Zafereo M., Cabanillas M.E. Thyroid cancer: A review. JAMA. 2024; 331 (5): 425—435. PMID: 38319329
  10. Tran T.V., Rubino C., Allodji R., Andruccioli M., Bardet S., Diallo I., Dottorini M., Garsi J., Hall P., Henry-Amar M., Lamart S., Le Thai F., Lönn S., Ricard M., Schvartz C., Schlumberger M., Journy N., de Vathaire F. Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment. Br J Cancer. 2022; 127 (12): 2118—2124. PMID: 36224404
  11. Tsomartova D.A., Chereshneva Ye.V., Ivanova M.Yu., Pashin S.S., Kuznetsov S.L. Impact of Na+/− symporter to non-oncologic pathology of the thyroid. Medical News of North Caucasus. 2019; 1—1: 131—134 (In Russian). eLIBRARY ID: 37634577
  12. Yavuz S., Puckett Y. Iodine-131 uptake study. StatPearls, 2025. PMID: 32644709
  13. Dzhikiya E.L., Avilov O.N., Kiseleva Ya.Yu., Kulinich T.M., Bozhenko V.K. Sodium/iodide symporter (NIS): structure, function and role in in thyroid diseases. Vestnik of the Russian Scientific Center of Roentgenoradiology. 2018; 1: 3 (In Russian). eLIBRARY ID: 35121876
  14. Karpishchenko S.A., Beldovskaya N.Yu., Baranskaya S.V., Karpov A.A. Outcomes of endoscopic endonasal dacryocystorhinostomy in the treatment of secondary acquired nasolacrimal duct obstruction after radioiodine therapy. Practical medicine. 2018; 5: 23—27 (In Russian). eLIBRARY ID: 35653615
  15. Auttara-Atthakorn A., Sungmala J., Anothaisintawee T., Reutrakul S., Sriphrapradang C. Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials. Front Endocrinol (Lausanne). 2022; 13: 960265. PMID: 36105397
  16. Adramerinas M., Andreadis D., Vahtsevanos K., Poulopoulos A., Pazaitou-Panayiotou K. Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand? —Hormones (Athens). 2021; 20 (4): 669—678. PMID: 34143403
  17. Kostyaeva M.G., Eremina I.Z., Kastyro I.V. Morphology and physiology of the salivary glands. Head and Neck. 2022; 3: 81—87 (In Russian). eLIBRARY ID: 49444613
  18. Yaremenko A.I., Razumova A.Ya., Petrov N.L., Kutukova S.I., Vaaz A.L. Intraductal salivary gland surgery after radioiodine therapy. Medical Almanac. 2023; 2 (75): 89—93 (In Russian). eLIBRARY ID: 54126164
  19. Nakada K., Ishibashi T., Takei T., Hirata K., Shinohara K., Katoh S., Zhao S., Tamaki N., Noguchi Y., Noguchi S. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? —J Nucl Med. 2005; 46 (2): 261—6. PMID: 15695785
  20. Bohuslavizki K.H., Brenner W., Klutmann S., Hübner R.H., Lassmann S., Feyerabend B., Lüttges J., Tinnemeyer S., Clausen M., Henze E. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J Nucl Med. 1998; 39 (7): 1237—42. PMID: 9669401
  21. Levy H.A., Park C.H. Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer. Clin Nucl Med. 1987; 12 (4): 303—7. PMID: 3581610
  22. Haghighatafshar M., Nowshad R., Etemadi Z., Ghaedian T. The effect of chewing-gum on dose rate of salivary gland in differentiated thyroid carcinoma patients treated with radioiodine. Q J Nucl Med Mol Imaging. 2020; 64 (3): 321—325. PMID: 29696945
  23. Horvath E., Skoknic V., Majlis S., Tala H., Silva C., Castillo E., Whittle C., Niedmann J.P., González P. Radioiodine-induced salivary gland damage detected by ultrasonography in patients treated for papillary thyroid cancer: Radioactive iodine activity and risk. Thyroid. 2020; 30 (11): 1646—1655. PMID: 32370663
  24. Sánchez Barrueco A., González Galán F., Alcalá Rueda I., Santillán Coello J.M., Barrio Dorado M.P., Villacampa Aubá J.M., Escanciano Escanciano M., Llanos Jiménez L., Mahillo Fernández I., Cenjor Español C. Incidence and risk factors for radioactive iodine-induced sialadenitis. Acta Otolaryngol. 2020; 140 (11): 959—962. PMID: 32815758
  25. Thorpe R.K., Foggia M.J., Marcus K.S., Policeni B., Maley J.E., Hoffman H.T. Sialographic analysis of radioiodine-associated chronic sialadenitis. Laryngoscope. 2021; 131 (5): E1450—E1456. PMID: 33200832
  26. Lee I.T., Chen W., Chen Q., Cole H.A., Bischoff L.A., Jessop A.C., Sobel R.K. Factors associated with radioactive iodine therapy-acquired nasolacrimal duct obstruction. Endocr Pract. 2022; 28 (12): 1210—1215. PMID: 35970353
  27. Grewal R.K., Larson S.M., Pentlow C.E., Pentlow K.S., Gonen M., Qualey R., Natbony L., Tuttle R.M. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med. 2009; 50 (10): 1605—10. PMID: 19759114

Downloads

Received

September 1, 2024

Accepted

May 21, 2025

Published on

July 5, 2025